2.75
price down icon0.36%   -0.010
after-market Dopo l'orario di chiusura: 2.80 0.05 +1.82%
loading

Okyo Pharma Limited Borsa (OKYO) Ultime notizie

pulisher
06:50 AM

OKYO Pharma Limited Stock Analysis and ForecastMarket-beating returns - PrintWeekIndia

06:50 AM
pulisher
02:40 AM

What analysts say about OKYO Pharma Limited stockMassive stock growth - PrintWeekIndia

02:40 AM
pulisher
05:02 AM

Will OKYO Pharma Limited stock benefit from AI tech trendsExplosive market performance - jammulinksnews.com

05:02 AM
pulisher
Jul 24, 2025

What institutions are buying OKYO Pharma Limited stock nowConsistently exceptional gains - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain - Pharmafile

Jul 24, 2025
pulisher
Jul 23, 2025

What drives OKYO Pharma Limited stock priceAccelerated wealth expansion - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is OKYO Pharma Limited a good long term investmentPhenomenal trading returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 21, 2025

OKYO Pharma Secures $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - VisionMonday.com

Jul 21, 2025
pulisher
Jul 19, 2025

OKYO Pharma CEO details positive results from Phase 2 urcosimod trialICYMI - Proactive financial news

Jul 19, 2025
pulisher
Jul 18, 2025

OKYO Pharma Secures $1.9M Non-Dilutive Funding to Advance Urcosimod Development - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain - Ophthalmology Times

Jul 18, 2025
pulisher
Jul 17, 2025

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding - GlobeNewswire

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma receives $1.9 million non-dilutive funding for lead drug development - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 17, 2025

Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics... - Proactive financial news

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Slides Despite Fresh R&D Funding - Baystreet.ca

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Okyo Pharma Obtains $1.9 Million Non-Dilutive Funding - MarketScreener

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO’s Market Whiplash: 86.16% YTD Rise, -1.66% Plunge in 30 Days - investchronicle.com

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - MarketScreener

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Secures $1.9M to Fast-Track Revolutionary Eye Pain Drug with No Current FDA Treatment - Stock Titan

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Australia

Jul 17, 2025
pulisher
Jul 16, 2025

OKYO Pharma Limited Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - MarketScreener

Jul 16, 2025
pulisher
Jul 16, 2025

OKYO Pharma Receives Positive Buy Rating from H.C. Wainwright - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation - TipRanks

Jul 16, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):